Physicians

Department / Division
Obstetrics/Gynecology / Gynecology Oncology

Address
DUMC 3079
Durham, NC 27710

Appointment Telephone
919-684-3765

Office Telephone
919-684-3765

Fax Telephone
919-684-8719

Training

• MD, Duke University School of Medicine, 1995

Residency

• OB/GYN, Duke University Medical Center, 1995-1999

Fellowship

• Gynecologic Oncology, Duke University Medical Center, 1999-2002

Other Training

• MHSc, Duke University, 2008

Clinical Interests
Gynecologic malignancies, premalignant disease of the cervix and vagina, radical pelvic surgery, chemotherapy, immunotherapy and radiation therapy, reconstructive pelvic surgery, laser surgery, complicated gynecologic surgery, hereditary ovarian cancer

Research Interests
I am interested in using health economic models to inform decisions related to gynecologic cancers.  Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer.  The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness.  This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer.  I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women.

Industry Relationships and Collaborations (What's this?)

This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

• Becton, Dickinson and Company
• Smith & Nephew plc

Representative Publications
Havrilesky LJ, Cragun JM, Calingaert B, Alvarez Secord A, Valea FA, Clarke-Pearson DL, Berchuck A, Soper JT. The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer. Gynecol Oncol. 2007 Feb;104(2):401-5. (2007) Abstract

Havrilesky LJ, Secord AA, Bae-Jump V, Ayeni T, Calingaert B, Clarke-Pearson DL, Berchuck A, Gehrig PA. Outcomes in surgical stage I uterine papillary serous carcinoma. Gynecol Oncol. 2007 Jun;105(3):677-82. (2007) Abstract

Havrilesky LJ, Secord AA, Kulasingam S, Myers E. Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis. Gynecol Oncol. 2007 Nov;107(2):211-8. (2007) Abstract

Cragun JM, Havrilesky LJ, Calingaert B, Synan I, Secord AA, Soper JT, Clarke-Pearson DL, Berchuck A. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol. 2005 Jun 1;23(16):3668-75. (2005) Abstract

Havrilesky LJ, Cragun JM, Calingaert B, Synan I, Secord AA, Soper JT, Clarke-Pearson DL, Berchuck A. Resection of lymph node metastases influences survival in stage IIIC endometrial cancer. Gynecol Oncol. 2005 Dec;99(3):689-95. (2005) Abstract

Havrilesky LJ, Kulasingam SL, Matchar DB, Myers ER. FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol. 2005 Apr;97(1):183-91. (2005) Abstract

Havrilesky LJ, Leath CA, Huh W, Calingaert B, Bentley RC, Soper JT, Alvarez Secord A. Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer. Gynecol Oncol. 2004 May;93(2):429-34. (2004) Abstract

Havrilesky LJ, Alvarez AA, Sayer RA, Lancaster JM, Soper JT, Berchuck A, Clarke-Pearson DL, Rodriguez GC, Carney ME. Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer. Gynecol Oncol. 2003 Jan;88(1):51-7. (2003) Abstract

Havrilesky LJ, Peterson BL, Dryden DK, Soper JT, Clarke-Pearson DL, Berchuck A. Predictors of clinical outcomes in the laparoscopic management of adnexal masses. Obstet Gynecol. 2003 Aug;102(2):243-51. (2003) Abstract

Havrilesky, LJ, Elbendary, A, Hurteau, JA, Whitaker, RS, Rodriguez, and Berchuck, A. Chemotherapy-induced apoptosis in epithelial ovarian cancers. Obstetrics and Gynecology 85, No. 6, 1007-1010, 1995. (1995)

Havrilesky, LJ, Hurteau, JA, Whitaker, RS, Elbendary, A, Wu, S, Rodriguez, GC, Bast, RC and Berchuck, A. Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor-beta. Cancer REsearch 55, 944-948, 1995. (1995)

Berchuck, A, Elbendary, A, Havrilesky, LJ, Rodriguez, GC and Bast, RC. Pathogenesis of ovarian cancers. J Soc Gynecol Invest 1, 181-190, 1994. (1994)

Elbendary, A, Berchuck, A, Davis, P, Havrilesky, LJ, Bast, RC, Iglehart, JD and Marks, JR. Transforming growth factor-Beta1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth & Differentiation 5, 1301-1307, 1994. (1994)